Lyssenko Nicholas N, Hata Mami, Dhanasekaran Padmaja, Nickel Margaret, Nguyen David, Chetty Palaniappan Sevugan, Saito Hiroyuki, Lund-Katz Sissel, Phillips Michael C
Lipid Research Group, Gastroenterology, Hepatology and Nutrition Division, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4318, USA.
Biochim Biophys Acta. 2012 Mar;1821(3):456-63. doi: 10.1016/j.bbalip.2011.07.020. Epub 2011 Aug 5.
The apoA-I molecule adopts a two-domain tertiary structure and the properties of these domains modulate the ability to form HDL particles. Thus, human apoA-I differs from mouse apoA-I in that it can form smaller HDL particles; the C-terminal α-helix is important in this process and human apoA-I is unusual in containing aromatic amino acids in the non-polar face of this amphipathic α-helix. To understand the influence of these aromatic amino acids and the associated high hydrophobicity, apoA-I variants were engineered in which aliphatic amino acids were substituted with or without causing a decrease in overall hydrophobicity. The variants human apoA-I (F225L/F229A/Y236A) and apoA-I (F225L/F229L/A232L/Y236L) were compared to wild-type (WT) apoA-I for their abilities to (1) solubilize phospholipid vesicles and form HDL particles of different sizes, and (2) mediate cellular cholesterol efflux and create nascent HDL particles via ABCA1. The loss of aromatic residues and concomitant decrease in hydrophobicity in apoA-I (F225L/F229A/Y236A) has no effect on protein stability, but reduces by a factor of about three the catalytic efficiencies (V(max)/K(m)) of vesicle solubilization and cholesterol efflux; also, relatively large HDL particles are formed. With apoA-I (F225L/F229L/A232L/Y236L) where the hydrophobicity is restored by the presence of only leucine residues in the helix non-polar face, the catalytic efficiencies of vesicle solubilization and cholesterol efflux are similar to those of WT apoA-I; this variant forms smaller HDL particles. Overall, the results show that the hydrophobicity of the non-polar face of the C-terminal amphipathic α-helix plays a critical role in determining apoA-I functionality but aromatic amino acids are not required. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010).
载脂蛋白A-I分子呈现出一种双结构域的三级结构,这些结构域的特性调节了形成高密度脂蛋白(HDL)颗粒的能力。因此,人类载脂蛋白A-I与小鼠载脂蛋白A-I的不同之处在于,它能形成更小的HDL颗粒;C端α螺旋在这一过程中很重要,而且人类载脂蛋白A-I的独特之处在于,在这个两亲性α螺旋的非极性面上含有芳香族氨基酸。为了理解这些芳香族氨基酸以及相关的高疏水性的影响,构建了载脂蛋白A-I变体,其中脂肪族氨基酸被取代,且总体疏水性或有或无降低。将变体人类载脂蛋白A-I(F225L/F229A/Y236A)和载脂蛋白A-I(F225L/F229L/A232L/Y236L)与野生型(WT)载脂蛋白A-I在以下能力方面进行比较:(1)溶解磷脂囊泡并形成不同大小的HDL颗粒,以及(2)介导细胞胆固醇外流并通过ABCA1产生新生HDL颗粒。载脂蛋白A-I(F225L/F229A/Y236A)中芳香族残基的缺失以及随之而来的疏水性降低对蛋白质稳定性没有影响,但使囊泡溶解和胆固醇外流的催化效率(V(max)/K(m))降低了约三倍;此外,形成的是相对较大的HDL颗粒。对于载脂蛋白A-I(F225L/F229L/A232L/Y236L),由于螺旋非极性面上仅存在亮氨酸残基而使疏水性得以恢复,其囊泡溶解和胆固醇外流的催化效率与WT载脂蛋白A-I相似;该变体形成更小的HDL颗粒。总体而言,结果表明C端两亲性α螺旋非极性面的疏水性在决定载脂蛋白A-I功能方面起着关键作用,但芳香族氨基酸并非必需。本文是名为《高密度脂蛋白形成与代谢进展:向约翰·F·奥勒姆致敬(1945 - 2010)》特刊的一部分。